The results show that mice receiving Drd3-sufficient or Drd3-deficient OT-I transgenic CD8+ T-cells displayed a significant reduction in tumour growth over time, compared with those mice that did not receive OT-I transgenic CD8+ T-cells (Figure 5B,C). The gene discussed is CD8A; the disease is neoplasm.